Pacira BioSciences (PCRX)

Company Profile

Pacira BioSciences, Inc.is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. The company's long-acting local analgesic, EXPAREL ® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, Pacira acquired the iovera° system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves.

Company profile

Ticker

PCRX

Exchange

NASDAQ

Website

www.pacira.com

CEO

David M. Stack

Incorporated

Delaware

Location

Florida

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies ...

Former names

Blue Acquisition Corp, PACIRA INC, Pacira Pharmaceuticals, Inc.

SEC CIK

0001396814

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Pacira Pharmaceuticals, Inc. • Pacira CryoTech, Inc. • Pacira Therapeutics, Inc. • Pacira Pharmaceuticals International, Inc. • Pacira Limited • Pacira Ireland Limited • Pacira Canada, Inc. ...

PCRX stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$64.75

Low target

$52.00

High target

$76.00

Latest filings (excl ownership)

View all

8-K

Pacira BioSciences Announces Departure of Yvonne Greenstreet from Board of Directors

28 Feb 23

Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results

28 Feb 23

8-K

Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million

5 Jan 23

8-K

Pacira BioSciences Reports Preliminary Net Product Sales of $57.5 Million for November 2022

13 Dec 22

8-K

Pacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2022

3 Nov 22

Pacira BioSciences Reports Third Quarter 2022 Financial Results

3 Nov 22

8-K

Pacira BioSciences Reports Preliminary Third Quarter 2022 Revenue of $167.5 Million

13 Oct 22

8-K

Pacira BioSciences Reports Preliminary Net Product Sales of $59.1 Million for August 2022

13 Sep 22

Transcripts

View all

PCRX

Earnings call transcript

2022 Q4

28 Feb 23

PCRX

Earnings call transcript

2022 Q3

3 Nov 22

PCRX

Earnings call transcript

2022 Q2

3 Aug 22

PCRX

Earnings call transcript

2022 Q1

4 May 22

PCRX

Earnings call transcript

2021 Q4

24 Feb 22

PCRX

Earnings call transcript

2021 Q3

3 Nov 21

PCRX

Earnings call transcript

2021 Q2

4 Aug 21

PCRX

Earnings call transcript

2021 Q1

4 May 21

PCRX

Earnings call transcript

2020 Q4

25 Feb 21

PCRX

Earnings call transcript

2020 Q3

29 Oct 20

Latest ownership filings

View all

CHARLES ANTHONY LARANJEIRA

16 Jun 22

Financial summary

Financial statements Chart PCRX financial data

Quarter (USD)	Dec 22	Sep 22	Jun 22	Mar 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	104.14 mm	104.14 mm	104.14 mm	104.14 mm	104.14 mm	104.14 mm
Cash burn (monthly)	1.76 mm	40.12 mm	6.02 mm	(no burn)	(no burn)	(no burn)
Cash used (since last report)	4.92 mm	112.07 mm	16.82 mm	n/a	n/a	n/a
Cash remaining	99.22 mm	-7.93 mm	87.32 mm	n/a	n/a	n/a
Runway (months of cash)	56.3	-0.2	14.5	n/a	n/a	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2022

PCRX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	268	264	+1.5%
Opened positions	49	20	+145.0%
Closed positions	45	38	+18.4%
Increased positions	93	114	-18.4%
Reduced positions	90	80	+12.5%

13F shares	Current	Prev Q	Change
Total value	1.84 tn	2.88 bn	+63796.5%
Total shares	48.98 mm	48.65 mm	+0.7%
Total puts	56.20 k	92.30 k	-39.1%
Total calls	16.10 k	47.50 k	-66.1%
Total put/call ratio	3.5	1.9	+79.6%

Largest owners	Shares	Value	Change
BLK Blackrock	7.25 mm	$279.98 bn	+1.4%
Vanguard	4.93 mm	$190.16 bn	+1.2%
MCQEF Macquarie	2.04 mm	$78.65 bn	-30.6%
Armistice Capital	1.89 mm	$73.05 bn	+18.8%
Baillie Gifford & Co	1.87 mm	$72.07 bn	+1.0%
STT State Street	1.62 mm	$62.38 bn	NEW
Renaissance Technologies	1.59 mm	$61.40 bn	-9.5%
Loomis Sayles & Co L P	1.47 mm	$56.94 bn	+2.3%
IVZ Invesco	1.36 mm	$52.53 bn	+19.0%
Stephens Investment Management	1.17 mm	$45.54 bn	-0.1%

Largest transactions	Shares	Bought/sold	Change
STT State Street	1.62 mm	+1.62 mm	NEW
MCQEF Macquarie	2.04 mm	-896.75 k	-30.6%
Millennium Management	1.15 mm	+683.68 k	+146.1%
Westfield Capital Management	29.96 k	-490.74 k	-94.2%
Norges Bank	402.83 k	+402.83 k	NEW
Spyglass Capital Management	868.69 k	-383.66 k	-30.6%
Armistice Capital	1.89 mm	+300.00 k	+18.8%
Wellington Management	663.06 k	-294.01 k	-30.7%
Emerald Advisers	224.63 k	-269.67 k	-54.6%
Citadel Advisors	287.37 k	+265.83 k	+1234.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

PCRX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
5 Jan 23	Anthony Molloy	Common Stock	Sell	Dispose S	No	Yes	38.31	546	20.92 k	19,450
4 Jan 23	Anthony Molloy	Common Stock	Sell	Dispose S	No	No	39.093	158	6.18 k	19,996
7 Oct 22	Reinhardt Max	Common Stock	Sell	Dispose S	No	Yes	58	1,380	80.04 k	31,378
3 Aug 22	Jonathan Slonin	Common Stock	Sell	Dispose S	No	No	55.7	308	17.16 k	37,079
3 Aug 22	Roy Winston	Common Stock	Sell	Dispose S	No	No	55.7	476	26.51 k	44,992
11 Jul 22	Hastings Paul J	Common Stock	Sell	Dispose S	No	Yes	56.95	533	30.35 k	7,179